Our study provides evidence for a FcyRIIIa V allele-restricted pCR benefit from neoadjuvant trastuzumab plus lapatinib in HER2 + BC .The Pharmacogenomics Journal advance online publication , 5 July 2016 ; doi :10.1038 / tpj .2016.51 .